9 7 8 1 6
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
被硒覆盖的纳米结构脂质载体，用于小檗碱口服给药以达到协同降糖作用
Authors Yin J, Hou Y, Yin Y, Song X
Received 22 June 2017
Accepted for publication 14 October 2017
Published 6 December 2017 Volume 2017:12 Pages 8671—8680
DOI https://doi.org/10.2147/IJN.S144615
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Govarthanan Muthusamy
Peer reviewer comments 3
Editor who approved publication: Dr Linlin Sun
Abstract: Diabetes mellitus is
an incurable metabolic disorder that seriously threatens human health. At
present, there is no effective medication available to defeat it. This work
intended to develop selenium-coated nanostructured lipid carriers (SeNLCs) for
enhancing the oral bioavailability and the curative effect of berberine, an
antidiabetic phytomedicine. Berberine-loaded SeNLCs (BB-SeNLCs) were prepared
by hot-melt dispersion/homogenization procedure followed by in situ reduction.
BB-SeNLCs were characterized by particle size, morphology, entrapment
efficiency (EE) and in vitro release. Pharmacokinetics of berberine solution,
berberine-loaded NLCs (BB-NLCs) and BB-SeNLCs were studied in Sprague Dawley
rats administered by oral gavage. The prepared BB-SeNLCs were around 160 nm in
particle size with an EE of 90%. In addition, BB-SeNLCs exhibited a better
sustained release of berberine compared to the plain NLCs. After oral
administration, BB-SeNLCs greatly enhanced the oral bioavailability of
berberine, which was approximately 6.63 times as much as that of berberine
solution. The hypoglycemic effect of BB-SeNLCs was also significantly superior
to that of BB-NLCs and berberine solution. It turned out that sustained drug
release and good intestinal absorption, plus the synergy of selenium, were
basically responsible for enhanced oral bioavailability and hypoglycemic
effect. Our findings show that SeNLCs are promising nanocarriers for oral
delivery of berberine to strengthen the antidiabetic action.
Keywords: berberine, diabetes mellitus, nanostructured lipid carriers, selenium, bioavailability
Keywords: berberine, diabetes mellitus, nanostructured lipid carriers, selenium, bioavailability
